A Phase 2 Randomized Double-Blind Placebo-Controlled Crossover Study Assessing The Ability Of Esreboxetine (PNU-165442g) To Improve Cognitive Function In Fibromyalgia Patients.

Trial Profile

A Phase 2 Randomized Double-Blind Placebo-Controlled Crossover Study Assessing The Ability Of Esreboxetine (PNU-165442g) To Improve Cognitive Function In Fibromyalgia Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2009

At a glance

  • Drugs Esreboxetine (Primary)
  • Indications Fibromyalgia
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Jul 2009 Actual patient number (89) added as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top